Differential time preferences for money and quality of life

PharmacoEconomics

Volumn 32, Issue 4, 2014, Pages 411-419

  Parouty, M B Y ^a   Le, H H ^a   Krooshof, D ^a   Postma, M J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EDUCATIONAL STATUS; EMPIRICISM; FEMALE; HEALTH STATUS; HUMAN; INCOME; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MONEY; OPTIMISM; PESSIMISM; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; TIME; ATTITUDE TO HEALTH; DELAY DISCOUNTING; NETHERLANDS; PSYCHOLOGY; QUALITY ADJUSTED LIFE YEAR;

ATTITUDE TO HEALTH; DELAY DISCOUNTING; FEMALE; HUMANS; MALE; NETHERLANDS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; TIME FACTORS;

EID: 84897553808     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0124-8     Document Type: Article

References (35)

1. http://www.ispor.org/PEguidelines.
2. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399-408.
3. Westra TA, Parouty MBY, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, Daemen T, Wilschut JC, Boersma C, Postma MJ. On discounting health gains from human papilloma virus vaccination. Value Health. 2012;15:562-7.
4. Rozenbaum H, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccin. 2011;10:187-99.
5. Hubben GAA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ. Enhanced decision support for policy makers using a web interface to health-economic models - illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2007;25:3669-78.
6. Postma MJ. Public health economics of vaccines in the Netherlands: methodological issues and applications. J Public Health. 2008;16:267-73.
7. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. ISBN 978-0-19-510824-8. Newyork: Oxford University Press; 1996.
8. Olsen JA. On what basis should health be discounted? Health Econ. 1993;12:39-53.
9. Keeler EB, Cretin S. Discounting of life-saving and other non-monetary effects. Manag Sci. 1983;29:300-6.
10. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ. 2001;10:587-99.
11. Klok RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ. Towards a healthier discount procedure. Exp Rev Pharmacoecon Outcomes Res. 2005;5:59-63.
12. Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH. Need for differential discounting of costs and health effects in cost-effectiveness analyses. BMJ. 2005;331:446-8.
13. Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ. 2006;15:1-4.
14. Federaal Kenniscentrum voor de Gezondheidszorg (KCE). Richtlijnen voor Farmaco-economische Evaluaties in België. Brussels: KCE 2008.
15. College voor Zorgverzekeringen (CVZ). Richtlijnen voor Farmaco-economisch Onderzoek; geactualiseerde versie. Dieman: CVZ 2006.
16. Rosati AG, Stevens JR, Hauser MD. The effect of handling time on temporal discounting in two New World primates. Anim Behav. 2006;71:1379-87.
17. http://www.hm-treasury.gov.uk.
18. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis. 2008;8(11):727-33.
19. Bazelon B. Discounting in the long term. Loyala Los Angeles Law Rev. 2002;35(1):277.
20. Bos JM, Beutels P, Annemans L, Postma MJ. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics. 2004;22(18):1171-9.
21. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics. 2006;24(12):1273-4.
22. Parouty MB, Pehlivanoglou P, Krooshof DGM, Postma MJ. On the empirical evidence in discounting. Exp Rev Pharmacoecon Outcomes Res. 2013;13(4):523-47.
23. Oreopoulos P, Salvanes GK. Priceless: the nonpecuniary benefits of schooling. J Econ Perspect. 2011;25(1):159-84.
24. Bamford C, Lagattuta KH. Looking on the bright side: children's knowledge about the benefits of positive versus negative thinking. Child Dev. 2011;83(2):667-82.
25. Berndsen M, van der Pligt J. Time is on my side: optimism in intertemporal choice. Acta Psychologica. 2001;108:173-86.
26. Cropper ML, Aydede SK, Portney PR. Rates of time preference for saving lives. Am Econ Rev. 1992;82(2):469-72.
27. Becker GS, Mulligan CB. The endogenous determination of time preference. Q J Econ. 1997;112(3):729-58.
28. Fischer I. The theory of interest rate. New York: Macmillan; 1930.
29. Lazaro A, Barberan R, Rubio E. Private and social time preferences for health and money: an empirical estimation. Health Econ. 2001;10(4):351-6.
30. Johannesson M, Johansson PO. Saving lives in the present versus saving lives in the future - is there a framing effect? J Risk Uncertain. 1997;15:167-76.
31. Cairns J, Van Der Pol M. The estimation of marginal time preference in a UK-wide sample (TEMPUS) project. Health Technol Assessm. 2000;4(1):1-83.
32. Walker DG, Hutubessy R, Beutels P. WHO guide for standardization of economic evaluations of vaccination programmes. Vaccine. 2010;28(11):2356-9.
33. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ. 1992;1(1):71-6.
34. Postma MJ, Parouty MBY, Westra TA. Accumulating evidence for the case of differential discounting. Expert Review of Clinical Pharmacology. Expert Rev Clin Pharmacol. 2013;6(1):1-3.
35. Gravelle H, Brouwer W, Niessen L, Postma MJ, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 2007;16(3):307-17.